Abstract 93P
Background
New predictive biomarkers for cetuximab-resistance for patients with RAS wild-type colorectal liver metastases (CRLM).
Methods
216 patients with initially unresectable liver-limited RAS wild-type CRLM were identified from previous clinical studies. Among these patients, 103 patients received chemotherapy (mFOLFOX6 or FOLFIRI) plus cetuximab, and 113 received chemotherapy alone as first-line treatment. Next-generation sequencing of primary tumors was done for single nucleotide polymorphism according to custom panel. The patients receiving cetuximab-based chemotherapy were divided into two groups: one group was cetuximab-resistant group and the other group was cetuximab-sensitive group. Potential predictive biomarkers were determined by “random forest" machine learning.
Results
Ten potential predictive genes, namely RET, PTPN11, FLT3, AKT1, ACTN4, ERBB4, FGFR3, MDC1, CUL9, and ZNF462, were identified. In the cohort of cetuximab-based chemotherapy, patients with all-wild-type genes had markedly improved median progression-free survival (12.0 vs. 4.0 months, P < 0.0001) and overall survival (37.0 VS. 24.0 months, P < 0.0001) compared with those with gene mutation; In the cohort of at-least-one gene mutation, patients receiving chemotherapy alone had comparable median PFS (4.0 VS. 4.0 months, P = 0.9498). Moreover, mutated are more common in patients with right-sided colon cancer.
Conclusions
Ten new predictive mutations help to refine the selection of RAS and BRAF wild-type metastatic colorectal cancer patients candidates for anti-EGFRs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract